日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The 2025 Nobel Prize in Physiology or Medicine - a bridge to peripheral immune tolerance

2025年诺贝尔生理学或医学奖——通往外周免疫耐受的桥梁

Bluestone, Jeffrey A

Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study

RADIOHEAD 患者免疫检查点抑制剂反应、免疫相关不良事件和类固醇使用之间的关联:一项前瞻性泛肿瘤队列研究

Quandt, Zoe; Lucas, Anastasia; Liang, Samantha I; Yang, EnJun; Stone, Samantha; Fadlullah, Muhammad Zaki Hidayatullah; Bayless, Nicholas L; Marr, Sara Siebel; Thompson, Marshall A; Padron, Lacey J; Bucktrout, Samantha; Butterfield, Lisa H; Tan, Aik Choon; Herold, Kevan C; Bluestone, Jeffrey A; Anderson, Mark S; Spencer, Christine N; Young, Arabella; Connolly, John E

The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation

Teplizumab 的故事:如何在临床转化中不迷失方向

Chatenoud, Lucienne; Herold, Kevan C; Bach, Jean-François; Bluestone, Jeffrey A

Rebalancing the Immune System to Treat Type 1 Diabetes

重新平衡免疫系统以治疗1型糖尿病

Muller, Yannick D; Ho, Patrick; Bluestone, Jeffrey A; Tang, Qizhi

Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applications

调节性T细胞的转录指纹图谱:确保细胞治疗应用的质量

Cheng, Zhang; Wang, Li-Jie; Honaker, Yuchi; Cincotta, Steven A; Page, Claire E; Vollhardt, Sydney; Yuan, Victor; Long, S Alice; Xiao, Yuanyuan; Beilke, Joshua N; Arron, Joseph R; Bluestone, Jeffrey A

Treg cell therapy manufacturability: current state of the art, challenges and new opportunities

Treg细胞疗法生产工艺:现状、挑战与新机遇

Stoops, Janelle; Morton, Tara; Powell, James; Pace, Amanda L; Bluestone, Jeffrey A

Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy

受体锚定的正交IL-2增强调节性T细胞疗法

Indart, Alyssa; Lyu, Huiyun; Nguyen, Vinh Q; Rosenthal, Wendy; Jang, Sophie S; Chen, Yue; Jude, Kevin; Su, Leon; Garcia, K Christopher; Bluestone, Jeffrey A; Tang, Qizhi

Opportunities for Treg cell therapy for the treatment of human disease

Treg细胞疗法在治疗人类疾病方面的机遇

Bluestone, Jeffrey A; McKenzie, Brent S; Beilke, Joshua; Ramsdell, Fred

Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

伊马替尼治疗新发1型糖尿病患者:一项多中心、随机、双盲、安慰剂对照的II期试验

Gitelman, Stephen E; Bundy, Brian N; Ferrannini, Ele; Lim, Noha; Blanchfield, J Lori; DiMeglio, Linda A; Felner, Eric I; Gaglia, Jason L; Gottlieb, Peter A; Long, S Alice; Mari, Andrea; Mirmira, Raghavendra G; Raskin, Philip; Sanda, Srinath; Tsalikian, Eva; Wentworth, John M; Willi, Steven M; Krischer, Jeffrey P; Bluestone, Jeffrey A

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

免疫检查点免疫疗法后免疫相关不良事件的临床前和临床模型开发:来自SITC和AACR的视角

Bayless, Nicholas L; Bluestone, Jeffrey A; Bucktrout, Samantha; Butterfield, Lisa H; Jaffee, Elizabeth M; Koch, Christian A; Roep, Bart O; Sharpe, Arlene H; Murphy, William J; Villani, Alexandra-Chloé; Walunas, Theresa L